gemcitabine has been researched along with pasireotide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bousquet, C; Bousquet-Dubouch, MP; Breibach, F; Chalabi-Dchar, M; Cordelier, P; Delisle, MB; Duluc, C; Gayral, M; Martineau, Y; Mathonnet, M; Moatassim-Billah, S; Perraud, A; Pyronnet, S; Samain, R; Schmid, H; Tomasini, R | 1 |
| Fulp, WJ; Jump, H; Kim, R; Mahipal, A; Shibata, D; Siegel, EM; Springett, GM; Suleiman, Y | 1 |
1 trial(s) available for gemcitabine and pasireotide
| Article | Year |
|---|---|
Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Somatostatin | 2015 |
1 other study(ies) available for gemcitabine and pasireotide
| Article | Year |
|---|---|
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cells, Cultured; Deoxycytidine; Disease Models, Animal; Drug Resistance; Fibroblasts; Gemcitabine; Heterografts; Humans; Mice, Nude; Phosphoproteins; Somatostatin; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |